Effect of anti-retroviral therapy and prophylaxis against opportunistic diseases on survival of patients with AIDS;Efecto del tratamiento antirretrovírico y de la profilaxis para enfermedades oportunistas en la supervivencia de los pacientes con SIDA

Revista Clinica Espanola

Volumn 200, Issue 4, 2000, Pages 187-192

  Galvez Hermoso C ^a   Blanco Quintana, F ^a   Del Amo Valero, J ^b   Diez Ruiz Navarro M ^b   Soriano Vazquez V ^a   Gonzalez Lahoz J ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

AIDS; Anti retroviral therapy; HIV; Pneumocystis carinii prophylaxis; Survival

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AIDS RELATED COMPLEX; ARTICLE; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW UP; HUMAN; IMMUNOLOGY; MALE; MORTALITY; PNEUMOCYSTIS PNEUMONIA; RETROSPECTIVE STUDY; RISK; SURVIVAL RATE; TUBERCULOSIS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PNEUMONIA, PNEUMOCYSTIS; RETROSPECTIVE STUDIES; RISK; SURVIVAL RATE; TUBERCULOSIS;

EID: 0034169970     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0014-2565(00)70603-5     Document Type: Article

References (40)

1. Reeves G, Overton S. Preliminary survival analysis of UK AIDS data. Lancet 1988; 16:880.
2. Mocroft A, Youle M, Morcinek J, et al. Survival after diagnosis of AIDS: a prospective observational study of 2625 patients. BMJ 1997; 314:409-413.
3. Dunne M, Ruskin H, Mulcahy F. Survival with AIDS in Ireland. AIDS 1997; 11:1.281-1.290.
4. Hillman R, Beck E, Mandalia S, et al. Survival and treatment of AIDS patients 1984-1993: experience of a smaller East London HIV centre. Genitourim Med 1997; 73:44-48.
5. Van Benthem B, Veugelers P, Cornelisse P, et al. Is AIDS a floating point between HIV seroconversion and death? Insights from the Tricontinental Seroconverter Study. AIDS 1998; 12:1.039-1.045.
6. Petruckevitch A, Del Amo J, Phillips A, et al. Disease progression and survival following specific AIDS-defining conditions: a retrospective cohort study of 2048 HIV-infected persons in London. AIDS 1998; 12:1.007-1.013.
7. Del Amo J, Petruckevitch A, Phillips A, et al. Disease progression and survival in HIV-1-infected Africans in London. AIDS 1998; 12:1.203-1.209.
8. Rabeneck L, Hartigan P, Huang I, Souchek J, Wray N. Predicting outcomes in HIV-infected veterans: II. Survival after AIDS. J Clin Epidemiol 1997; 50:1.241-1.248.
9. 3. J AIDS Hum Retrovirol 1997; 15:346-355.
10. Clark R, Bessinger R. Clinical manifestations and predictors of survival in older women infected with HIV. J AIDS Hum Retrovirol 1997; 15:341-345.
11. Lemp G, Hirozawa A, Cohen J, Derish P, McKinney K, Hernández S. Survival for women and men with AIDS. J Infect Dis 1992; 166:74-79.
12. Perneger T, Sudre P, Lundgren J, Hirschel B. Does the onset of tuberculosis in AIDS predict shorter survival? Results of a cohort study in 17 European countries over 13 years. BMJ 1995; 311:1.468-1.471.
13. Caylá J, Artazcoz L, Iglesias B, Jansá J, Plasencia A. Epidemiología del SIDA en Barcelona (1981-1991) (II). Estudio de mortalidad y de supervivencia. Med Clín (Barc) 1994; 102:129-135.
14. Anónimo. Changes in the incidence of AIDS and in AIDS deaths: the effects of antiretroviral treatment. CDRW 1997; 7:381.
15. Hogg R, O'Shaughnessy M, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet 1997; 349:1.294.
16. Michaels S, Clark M, Kissinger P. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 339:405-406.
17. Spira R, Marimoutou C, Binquet C, Lacoste D, Dabis F. Rapid change in the use of antiretroviral agents and improvement in a population of HIV-infected patients: France, 1995 to 1997. J AIDS Hum Retrovirol 1998; 18:358-364.
18. Needham D, Hogg R, Yip B, O'Shaughnessy M, Schechter M, Montaner J. The impact of antiretroviral therapy on AIDS survival observed in a province-wide drug treatment programme. Int J STD & AIDS 1998; 9:370-371.
19. Palella F, Kathleen M, Moorman A, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-860.
20. Chaisson R, Gallant J, Keruli J, Moore R. Impact of opportunistic disease on survival in patients with HIV infection AIDS 1998; 12:29-33.
21. Beck E, Mandalia S, Miller D, Harris J. Hospital service interventions and improving survival of AIDS patients St Mary's Hospital, London, 1982-1991. Int J STD & AIDS 1998; 9:280-290.
22. Laing R, Brettle R, Leen C, Hulks G. Features and outcome of Pneumocystis carinii pneumonia according to risk category for HIV infection. Scand J Infect Dis 1997; 29:57-61.
23. Osmond D, Charlebois E, Lang W, Shiboski S, Moss A. Changes in AIDS survival time in two San Francisco cohorts of homosexual men, 1983 to 1993. JAMA 1994; 271:1.083-1.087.
24. Bucher H, Griffith L, Guyatt G, et al. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS 1999; 13:501-507.
25. Anónimo. USPHS/IDSA Prevention of Opportunistic Infections Working Group. Preface to the 1997 USPHS/ IDSA Guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Clin Infect Dis 1997; 25 (suppl 3):299-312.
26. Anónimo. Revised CDC classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults MMWR 1992; 41 (RR-17):1-19.
27. Lundgren J, Pedersen C, Clumeck N, et al. Survival differences in European patients with AIDS, 1979-89. BMJ 1994; 308:1.068-1.073.
28. Alberdi J, López-Gay D, Ferreras A, Nieto E. Descenso brusco de la mortalidad por VIH/SIDA en la Comunidad de Madrid. Med Clín (Barc) 1998; 110:662-664.
29. Jahnke N, Montesori V, Hogg R, Anis A, O'Shaughnessy M, Montaner J. Impact of triple drug therapy on morbidity, mortality and cost. AIDS Reviews 1999; 1:57-60.
30. Domingo P, Guardiola J, Ris J, Nolla J. The impact of new antiretroviral regimes on HIV-associated hospital admissions and deaths. AIDS 1998; 12:529-530.
31. Soriano V, Rodríguez-Rosado R, Silva T, González-Lahoz J. Ingresos y defunciones en la unidad de VIH antes y después de los inhibidores de la proteasa. Rev Clín Esp 1998; 198:715.
32. Fätkenheuer G, Theisen A, Rockstroh J, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997; 11:F113-F116.
33. Rodríguez-Rosado R, Jiménez-Nácher I, Soriano V, Antón P. Virological failure and adherence to antiretroviral therapy in HIV-infected patients. AIDS 1998; 12:1.112-1.113.
34. Furrer H, Egger M, Opravil M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. N Engl J Med 1999; 340:1.301-1.306.
35. Weverling G, Mocroft A, Ledergerber B, et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. Lancet 1999; 353:1.293-1.298.
36. Anónimo. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR 1998; 47 (RR-20):1-58.
37. Gordin F, Matts J, Miller C, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. N Engl Med 1997; 337:315-320.
38. Anónimo. Tuberculosis e infección por VIH. Recomendaciones del Consejo Asesor Clínico del Plan Nacional sobre el SIDA. Ministerio de Sanidad y Consumo, Marzo 1995.
39. Moreno S, Baraia-Etxaburu J, Miralles P, Berenguer J, Cosín J, Bernaldo de Quirós J. Tuberculin reaction size in patients infected with HIV. AIDS 1995; 9:1.289-1.290.
40. Anónimo. Protease inhibitors and anti-tuberculosis treatment. Department of Health, City of New York. TBC Fact sheet 1997; 2 i:219.